More information about this award

Award Information PDF
Application Deadline: September 1, 2017

Healthy Minds Canada and Pfizer Canada are strongly committed to improving the health and quality of life of Canadians living with mental illness. The Healthy Minds Canada/Pfizer Canada Workplace Depression Awards are designed to help advance clinical research and patient care in psychiatry by supporting Canadian investigators. All submitted proposals will be evaluated by an external independent review committee comprised of Canadian medical research experts.


There are two awards valued at $25,000 each in the following areas of interest:

  • Research assessing the impact of rapid and early optimization of treatment in depression:
    • On depression and level of functional improvement in workplace productivity, presenteeism and absenteeism
    • To minimize depression relapse in the workplace
    • To minimize the incidence of/mitigate the risks for depression in the workplace (e.g. quality improvement research).
  • Research assessing the impact of psychiatric drug substitution on medication effectiveness and functional recovery in depression with respect to:
    • Efficacy, tolerability and adherence to medication following brand-to-generic switches
    • Efficacy, tolerability and adherence to medication following generic-to-generic switches
    • Understand patient, pharmacist and physician awareness of the potential impact of switches (brand-to-generic or generic-to-generic medications)

Applications & Process:

Applications are due by September 1, 2017              .

Applications will be received via email at [email protected]

Questions about the application process should be sent to [email protected]

Please note that our scientific review committee will review all applications starting in October 2017 and the winner will be announced at a ceremony at HMC’s Silver Dinner (November 13, 2017)

Eligibility: